Format

Send to

Choose Destination
Expert Opin Drug Discov. 2014 Nov;9(11):1319-31. doi: 10.1517/17460441.2014.956721. Epub 2014 Sep 24.

Current approaches for the discovery of drugs that deter substance and drug abuse.

Author information

1
National Institutes of Health, NIH Chemical Genomics Center, National Center for Advancing Translational Sciences , Bethesda, MD , USA +1 301 217 5721 ; +1 301 217 5736 ; asimeono@mail.nih.gov.

Abstract

INTRODUCTION:

Much has been presented and debated on the topic of drug abuse and its multidimensional nature, including the role of society and its customs and laws, economical factors, and the magnitude and nature of the burden. Given the complex nature of the receptors and pathways implicated in regulation of the cognitive and behavioral processes associated with addiction, a large number of molecular targets have been interrogated during recent years to discover starting points for development of small-molecule interventions.

AREAS COVERED:

This review describes recent developments in the field of early drug discovery for drug abuse interventions with an emphasis on the advances published during the 2012 - 2014 period.

EXPERT OPINION:

Technologically, the processes/platforms utilized in drug abuse drug discovery are nearly identical to those used in the other disease areas. A key complicating factor in drug abuse research is the enormous biological complexity surrounding the brain processes involved and the associated difficulty in finding 'good' targets and achieving exquisite selectivity of treatment agents. While tremendous progress has been made during recent years to use the power of high-throughput technologies to discover proof-of-principle molecules for many new targets, next-generation models will be especially important in this field. Examples include: seeking advantageous drug-drug combinations, the use of automated whole-animal behavioral screening systems, advancing our understanding of the role of epigenetics in drug addiction and the employment of organoid-level 3D test platforms (also referred to as tissue-chip or organs-on-chip).

KEYWORDS:

addiction; combination therapy; drug abuse; drugs of abuse; high-throughput screening; receptor agonist; substance abuse

PMID:
25251069
PMCID:
PMC4633284
DOI:
10.1517/17460441.2014.956721
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center